Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

RVT-101 for Mild to Moderate Alzheimer's Disease with Donepezil (MINDSET)

Start: October 2015
End: September 2017
Enrollment: 1150

What Is This Study About?

This clinical trial will test the experimental drug RVT-101 as an add-on treatment to donepezil in people with mild to moderate Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 85 Years

Must have:

  • Alzheimer's disease
  • Mini-Mental State Examination score of 12-24 at screening or 10-26 at initial visit
  • Hachinski Ischaemia score of 4 or less at screening
  • Women must be of non-childbearing potential, surgically sterile, or willing to use adequate birth control; men who are sexually active will also be required to use adequate birth control
  • Ability to comply with cognitive and other testing
  • Reliable caregiver who can report on subject's status 

Must NOT have:

  • Non-Alzheimer's cause of dementia, for example, diagnosis of vascular dementia
  • Unusual clinical features or clinical course of dementia that suggests alternate dementia diagnosis, including frontotemporal dementia or Lewy body dementia
  • History of significant psychiatric illness, such as schizophrenia or bipolar affective disorder
  • Any clinically relevant disease that makes the subject unsuitable for the study

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Who Is the General Study Contact?

For more information about this clinical trial, visit http://alzheimersglobalstudy.com/?as=11 or contact Axovant Clinical Trials at 646-495-8197 or mindset@axovant.comPlease refer to this study by its ClinicalTrials.gov identifier, NCT02585934.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Axovant Sciences, Ltd.

Source: ClinicalTrials.gov ID: NCT02585934

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health